Home | Member Login | Join/Renew | Jobs | Contact
October 25, 2018, Cure Today
The anti-PD-1 monoclonal antibody TSR-042 appeared to be safe and effective in the treatment of patients with microsatellite-high (MSI-H) endometrial cancer, according to preliminary results presented at the European Society for Medical Oncology (ESMO)'s 2018 Congress.
Read more.
563 Carter Court, Suite B, Kimberly, WI 54136920-560-5620 / 800-545-0636920-882-3655 (fax)Email: APAOG@badgerbay.co
Quick Links
About APAOGContact UsJoin as a Member